Shine Investment Advisory Services Inc. cut its stake in DexCom, Inc. (NASDAQ:DXCM) by 33.0% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 553 shares of the medical device company’s stock after selling 272 shares during the period. Shine Investment Advisory Services Inc.’s holdings in DexCom were worth $66,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently modified their holdings of the business. Vanguard Group Inc increased its stake in shares of DexCom by 11.5% during the third quarter. Vanguard Group Inc now owns 7,942,861 shares of the medical device company’s stock valued at $1,136,147,000 after purchasing an additional 816,247 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of DexCom by 17.2% during the fourth quarter. Geode Capital Management LLC now owns 1,042,131 shares of the medical device company’s stock valued at $124,776,000 after purchasing an additional 152,781 shares in the last quarter. Norges Bank bought a new position in shares of DexCom during the fourth quarter valued at approximately $107,191,000. Mackenzie Financial Corp increased its stake in shares of DexCom by 13.7% during the fourth quarter. Mackenzie Financial Corp now owns 767,971 shares of the medical device company’s stock valued at $92,003,000 after purchasing an additional 92,289 shares in the last quarter. Finally, Two Sigma Investments LP increased its stake in shares of DexCom by 596.5% during the fourth quarter. Two Sigma Investments LP now owns 731,059 shares of the medical device company’s stock valued at $87,581,000 after purchasing an additional 626,098 shares in the last quarter. Institutional investors and hedge funds own 97.96% of the company’s stock.
Shares of DXCM opened at $117.76 on Wednesday. The company has a market cap of $10.60 billion, a P/E ratio of 392.53 and a beta of 0.75. The company has a quick ratio of 7.32, a current ratio of 7.64 and a debt-to-equity ratio of 1.52. DexCom, Inc. has a twelve month low of $72.04 and a twelve month high of $156.16.
DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, February 21st. The medical device company reported $0.54 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.16 by $0.38. The company had revenue of $338.00 million during the quarter, compared to the consensus estimate of $331.60 million. DexCom had a negative net margin of 12.32% and a positive return on equity of 4.98%. The firm’s quarterly revenue was up 52.9% compared to the same quarter last year. During the same quarter last year, the firm earned $0.10 earnings per share. On average, sell-side analysts anticipate that DexCom, Inc. will post 0.46 EPS for the current fiscal year.
In other DexCom news, insider Andrew K. Balo sold 10,917 shares of DexCom stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $142.79, for a total value of $1,558,838.43. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Patrick Michael Murphy sold 400 shares of DexCom stock in a transaction that occurred on Friday, February 8th. The stock was sold at an average price of $142.76, for a total transaction of $57,104.00. The disclosure for this sale can be found here. Insiders have sold 95,048 shares of company stock valued at $13,395,403 in the last three months. 1.80% of the stock is owned by insiders.
A number of equities analysts have weighed in on the stock. Cowen raised their target price on shares of DexCom from $150.00 to $175.00 and gave the company an “outperform” rating in a research note on Friday, February 22nd. Canaccord Genuity raised their target price on shares of DexCom from $140.00 to $160.00 and gave the company a “buy” rating in a research note on Friday, February 22nd. Morgan Stanley raised their target price on shares of DexCom from $135.00 to $160.00 and gave the company an “equal weight” rating in a research note on Monday, February 25th. Piper Jaffray Companies raised their target price on shares of DexCom to $165.00 and gave the company an “overweight” rating in a research note on Wednesday, January 9th. Finally, UBS Group raised their target price on shares of DexCom from $135.00 to $140.00 and gave the company a “neutral” rating in a research note on Tuesday, January 8th. Six investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. DexCom currently has an average rating of “Buy” and a consensus price target of $149.53.
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
See Also: Conference Calls
Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.